Toxicities of gemcitabine in patients with severe hepatic dysfunction

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 750-754

  Teusink, Ashley C ^a   Hall, Philip D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Gemcitabine; Hepatic dysfunction; Liver failure; Neutropenia; Thrombocytopenia

Indexed keywords

BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CETUXIMAB; ERLOTINIB; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; MEDICAL RECORD REVIEW; METASTATIC BREAST CANCER; METASTATIC PANCREATIC CANCER; MONOTHERAPY; NEUTROPHIL COUNT; PANCREAS CANCER; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA;

ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; LEUKOCYTE COUNT; LIVER DISEASES; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 77950596828     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M587     Document Type: Article

References (9)

1. Field KM, Dow C, Michael M. Part I: liver function in oncology: biochemistry and beyond. Lancet Oncol 2008;9:1092-1100
2. Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist 2007;12:1070-1083 (Pubitemid 350007019)
3. Product information. Gemzar (gemcitabine HCL) for injection. Indianapolis, IN: Eli Lilly and Company, May 2006
4. Mano MS, Cassidy J, Canney P. Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treat Rev 2005;31:35-48 (Pubitemid 40246989)
5. Veltkamp SA, Pluim D, Tellingen O, Beijnen JH, Schellens JH. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and iv administration in mice. Drug Metab Dispos 2008;8:1606-1615
6. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-2787
7. Floyd, J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006;33:50-67 (Pubitemid 43214486)
8. Field KM, Michael M. Part II: liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008;9:1181-1190
9. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003, Published date: August 9, 2006. http://ctep.cancer.gov (accessed 2009 Apr 4)